Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
Tempus AI (NASDAQ: TEM) has announced a collaboration with United Therapeutics (UT) to develop AI-based medical device software for early detection of pulmonary hypertension (PH). This fatal heart and lung condition affects around 1% of the population. Despite available treatments, PH diagnosis is typically delayed by over two years. Tempus' AI algorithm, which analyzes ECG results to identify at-risk patients, was presented at the American Thoracic Society International Conference. The algorithm will be deployed in a prospective clinical study at up to 60 centers. Tempus aims to engage with the FDA for regulatory alignment.
- Tempus AI collaborates with United Therapeutics to develop AI-based software for early PH detection.
- Algorithm presented at the American Thoracic Society International Conference.
- Prospective clinical study planned at up to 60 centers.
- Engagement with FDA for regulatory alignment of the AI algorithm.
- PH diagnosis typically delayed by over two years despite available treatments.
Insights
The collaboration between Tempus AI and United Therapeutics to develop AI-based software for detecting undiagnosed pulmonary hypertension (PH) represents a significant breakthrough in precision medicine. Pulmonary hypertension is a severe illness affecting the heart and lungs, often leading to delayed diagnoses due to its complex nature. The algorithm's ability to analyze 12-lead ECG results swiftly and accurately is a major advantage, as it could significantly reduce the diagnosis time, potentially saving lives.
In the short-term, investors might see increased interest and partnerships in AI-driven healthcare solutions, leading to potential stock price appreciation. The long-term outlook could include widespread adoption of the technology, which may revolutionize the approach to diagnosing PH and possibly other conditions, having a lasting positive impact on both patient outcomes and the companies involved.
However, there are some drawbacks to consider. Regulatory hurdles with the FDA must be navigated carefully. The technology also needs thorough validation through prospective clinical studies to ensure its effectiveness and safety. Additionally, there's a risk that the algorithm may produce false positives or negatives, which could impact its credibility and adoption rate.
Overall, this innovation showcases the powerful potential of AI in medicine, but investors should watch closely for updates on clinical trial results and regulatory approvals.
From a financial perspective, the collaboration between Tempus AI and United Therapeutics is promising. The focus on developing AI-based tools for early detection of pulmonary hypertension aligns with the growing demand for precision medicine and advanced diagnostic tools. This could open new revenue streams for both companies, especially considering the high market need for better diagnostic solutions in cardiopulmonary diseases.
For Tempus AI, this partnership signifies an opportunity to diversify its product offerings and establish itself as a leader in AI-driven healthcare solutions. Positive results from the prospective clinical study could lead to regulatory approval, which in turn might drive revenue growth and enhance shareholder value.
United Therapeutics stands to benefit as well, as better diagnostic tools could lead to increased use of their existing and pipeline therapies for pulmonary hypertension. Investors should monitor the financial results and clinical milestones closely, as successful outcomes could lead to increased profitability and potentially higher stock valuations.
However, the financial forecast isn't without risks. The costs associated with development, clinical validation and regulatory approval can be substantial. If the technology fails to meet clinical endpoints or gain FDA approval, both companies could face financial setbacks. Thus, while the potential rewards are high, so are the risks.
PH is a fatal, progressive disease of the heart and lungs that affects approximately
Tempus’ research and development program will leverage Tempus Next, the company’s AI-enabled care pathway intelligence solution, to facilitate the deployment of the algorithm at participating centers. Clinicians will evaluate its ability to detect patients at risk of undiagnosed PH, and to track clinical outcomes of patients who are identified for further evaluation, within a prospective clinical study at up to 60 centers. Tempus and UT plan to collaborate on this study to investigate the clinical impact of this technology and gain new insights into the detection and diagnosis of PH. Tempus expects to engage with the Food and Drug Administration (FDA) to align on regulatory requirements and FDA expectations regarding validation of this novel AI-based algorithm.
“We aim to set a new standard for identifying patients with pulmonary hypertension by getting novel technology into the hands of clinicians to enable earlier diagnosis and more effective disease management,” said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. “Exploring this in a prospective multicenter study brings us one step closer to realizing the dream of data-driven precision medicine.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
| _____________________________________ | |
1,2 |
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3618–3731, https://doi.org/10.1093/eurheartj/ehac237 |
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding the expected outcomes and benefits of the collaboration with UT to study use of artificial intelligence to detect patients at risk for PH, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Final Prospectus filed with the Securities and Exchange Commission (“SEC”) on June 17, 2024, pursuant to Rule 424(b)(4) under the Securities Act, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625657815/en/
Tempus Communications
Erin Carron
media@tempus.com
Source: Tempus
FAQ
What is the collaboration between Tempus AI and United Therapeutics about?
When was the Tempus AI algorithm for PH detection presented?
What is the stock symbol for Tempus AI?
How many centers will participate in the prospective clinical study for the AI algorithm?
What is the expected outcome of the Tempus and United Therapeutics collaboration?
